FREMONT, Calif. / May 22, 2025 / Business Wire / Personalis, Inc . (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois. The presentations feature new data from clinical studies utilizing the NeXT Personal ® ultrasensitive ctDNA assay for residual and recurrent cancer detection.... Read More

FREMONT, Calif. / May 14, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Craig-Hallum 22 nd Annual Investor Conference on Wednesday, May 28, 2025, at The Depot Renaissance Hotel in Minneapolis, MN. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through... Read More

Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year FREMONT, Calif. / May 06, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights Delivered... Read More

100% of resectable Stage I-IV colorectal cancer relapses were detected ahead of imaging, with 87% of those relapses having been detected in the first eight weeks following surgery FREMONT, Calif. / Apr 28, 2025 / Business Wire / Personalis, Inc . (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced new interim analysis results of the VICTORI study showing strong performance of its... Read More

FREMONT, Calif. / Apr 22, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.... Read More

FREMONT, Calif. / Apr 22, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring data for the company’s NeXT Personal ® ultrasensitive ctDNA assay for residual and recurrent cancer detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 25-30,... Read More

FREMONT, Calif. / Mar 26, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a... Read More

FREMONT, Calif. / Mar 03, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust in the UK, published results from their early-stage breast cancer study in Annals of Oncology . In this groundbreaking study, the authors highlight advancements in... Read More

Full year revenue of $84.6 million represents a 15% year-over-year increase Cash balance of $185 million expected to provide runway to cash flow break-even FREMONT, Calif. / Feb 27, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights.... Read More

FREMONT, Calif. / Feb 18, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen's 45th Annual Health Care Conference on Monday, March 3, 2025, at the Boston Marriott Copley Place in Boston, MA. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through... Read More

FREMONT, Calif. / Feb 13, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results... Read More

FREMONT, Calif. / Jan 28, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 11, 2025, at The Cliff Lodge in Snowbird, UT. About Personalis, Inc. At Personalis, we are transforming the active management of... Read More

Results demonstrate the importance of ultra-sensitive ctDNA detection in lung cancer FREMONT, Calif. / Jan 13, 2025 / Business Wire / Personalis, Inc . (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London’s Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine. In this groundbreaking study funded by Cancer... Read More

Full year revenue of ~$84.6 million represents a 15% year-over-year increase Cash balance of ~$185.0 million expected to provide runway to cash flow break-even FREMONT, Calif.--( BUSINESS WIRE )-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2024 and preliminary cash balance.... Read More

FREMONT, Calif. / Dec 19, 2024 / Business Wire / Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis’ ImmunoID NeXT... Read More

Expanded collaboration to yield greater biopharma access to Personalis’ MRD solution FREMONT, Calif. / Dec 16, 2024 / Business Wire / Personalis, Inc . (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024... Read More

FREMONT, Calif. / Nov 20, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences: Piper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024 Fireside Chat Time: 12:30 pm Eastern Time Location: The Lotte New York Palace in New York, NY TD Cowen Diagnosing... Read More

41% Year-over-Year Increase in Revenue Driven by Strong Biopharma Growth of 96% Raising 2024 Revenue Guidance Due to Accelerating Growth Cash Balance of $143.7 Million Extends Expected Runway Into First-Half of 2027 FREMONT, Calif. / Nov 06, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30,... Read More

FREMONT, Calif. / Nov 05, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the Stifel 2024 Healthcare Conference on Tuesday, November 19, at 10:55 a.m. Eastern Time in New York, NY at the Lotte New York Palace Hotel. About Personalis, Inc. At Personalis, we are transforming the active management of cancer... Read More

FREMONT, Calif. / Oct 23, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial results on Wednesday, November 6, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent... Read More

Results continue to demonstrate the importance of ultra-sensitive ctDNA detection in lung cancer and immunotherapy FREMONT, Calif. / Sep 16, 2024 / Business Wire / Personalis, Inc . (Nasdaq: PSNL), a leader in MRD testing, announced findings presented this week at the European Society of Medical Oncology Congress (ESMO) Congress 2024 in Barcelona, Spain. Personalis’ NeXT Personal assay was designed to detect and monitor... Read More

FREMONT, Calif. / Aug 22, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Thursday, September 5, 2024 Presentation Time: 4:50 pm Eastern Time Location: Marriott Marquis in New York Lake Street 8th Annual... Read More

FREMONT, Calif. / Aug 19, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on August 15, 2024, a non-qualified stock option to purchase an aggregate of 75,000 shares of its common stock to Personalis’ new Executive Director, Market Access & Reimbursement under Personalis’ 2020... Read More

Tempus invests $36 million by exercising warrants and purchasing additional shares FREMONT, Calif. / Aug 16, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the recent ASCO... Read More

Strong Revenue Growth of 35% Year-over-Year Driven by 117% Growth from Biopharma Business Raises 2024 Full Year Revenue Guidance FREMONT, Calif. / Aug 07, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2024, and provided recent business accomplishments. Recent Business Accomplishments... Read More

FREMONT, Calif. / Jul 31, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate virtually at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 13, 2024. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We... Read More

FREMONT, Calif. / Jul 24, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent... Read More

FREMONT, Calif. / Jun 18, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that Chris Hall, CEO and President, will join a panel and speak at the TD Cowen 3 rd Annual Tools / Dx Revolution Conference on Tuesday, June 25, 2024 at 5:30 p.m. Eastern Time. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough... Read More

FREMONT, Calif. / Jun 13, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it has updated the ASCO data highlights conference call to Friday, June 21, 2024 at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. Personalis had previously announced it would host the conference call on Wednesday, June 19, 2024 at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time.... Read More

Personalis will host a webinar call on June 19th, 2024 at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time to present ASCO highlights from the conference FREMONT, Calif. / Jun 04, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL) announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL demonstrated that the Personalis NeXT Personal test had exceptional... Read More

FREMONT, Calif. / May 31, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal® , Personalis’ ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease (MRD) and recurrence in cancer. Members of Tempus’ commercial team can now engage in... Read More

FREMONT, Calif. / May 22, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company’s NeXT Personal ® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which... Read More

FREMONT, Calif. / May 17, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on May 15, 2024, a non-qualified stock option to purchase an aggregate of 85,000 shares of its common stock to Personalis’ new Vice President, Customer Experience under Personalis’ 2020 Inducement Plan. The... Read More

Raises full year revenue guidance due to greater pharma testing demand FREMONT, Calif. / May 08, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2024 ended March 31, 2024, and provided recent business highlights. Recent Business Highlights The analytical validation for the company’s NeXT Personal MRD test... Read More

FREMONT, Calif. / Apr 24, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2024 financial results on Wednesday, May 8, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.... Read More

FREMONT, Calif. / Mar 28, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23 rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to... Read More

FREMONT, Calif. / Mar 28, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San... Read More

Blood-based assay uses personalized tumor-informed approach designed to detect cancer recurrence early with an ultra-sensitive approach FREMONT, Calif. / Mar 26, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay. NeXT... Read More

FREMONT, Calif. / Mar 19, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on November 15, 2023 and March 15, 2024, non-qualified stock options to purchase an aggregate of 41,500 shares of its common stock to ten new employees under Personalis’ 2020 Inducement Plan. The 2020... Read More

FREMONT, Calif. / Feb 28, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights. Recent Business Highlights Obtained final Medicare coverage determination for its NeXT Dx® comprehensive tumor genomic profiling test, providing access for... Read More

FREMONT, Calif. / Feb 14, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results... Read More

FREMONT, Calif. / Jan 31, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Participating on Tuesday, February 13, 2024 at The Cliff Lodge in Snowbird, UT 44 th Annual Cowen Healthcare Conference Presenting on... Read More

Personalis to offer ClearNote’s patented Epigenomic Platform to its biopharmaceutical partners FREMONT, Calif. & SAN DIEGO / Jan 30, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health , Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s... Read More

FREMONT, Calif. / Jan 17, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 29,000 shares of its common stock to eight new employees under Personalis’ 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the... Read More

NeXT Dx helps clinicians make informed, personalized cancer treatment selections and match patients with clinical trials Access to NeXT Dx expands to the 66 million Medicare and Medicare Advantage beneficiaries FREMONT, Calif. / Jan 16, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its... Read More

FREMONT, Calif. / Jan 05, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023. Preliminary Fourth Quarter Revenue and Cash Balance Preliminary total company revenue is estimated to be $19.7 million in the fourth quarter of 2023, an increase of 18% compared with... Read More

Workforce restructuring and recent commercial collaboration help position company for long-term success FREMONT, Calif. / Dec 04, 2023 / Business Wire / Personalis, Inc. , a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff. By consolidating several functions for efficiency, this reduction is expected to reduce operating... Read More

Exclusive arrangement will expand market access to Personalis’ ultra-sensitive MRD test FREMONT, Calif. & CHICAGO / Nov 28, 2023 / Business Wire / Personalis, Inc. , a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc. , a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to co-commercialize NeXT Personal® Dx , Personalis’ whole... Read More

Increased third quarter revenue 23% to $18.2 million and increased full year guidance Presented data supporting NeXT Personal’s market leading sensitivity for cancer recurrence detection FREMONT, Calif. / Nov 07, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2023 and provided recent... Read More

NeXT Personal Dx is an ultra-sensitive test for detecting cancer from a blood sample Clinical data from groundbreaking TRACERx lung cancer study demonstrates significant sensitivity and lead time improvements in detecting cancer FREMONT, Calif. / Oct 26, 2023 / Business Wire / Personalis, Inc . (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the launch of the Early Access Program for... Read More

FREMONT, Calif. / Oct 24, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2023 financial results on Tuesday, November 7, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and... Read More

NeXT Personal ® ctDNA assay shown to be more sensitive and predictive of clinical outcomes in early-stage lung cancer patients Demonstrates importance of an ultra-sensitive ctDNA approach FREMONT, Calif. / Oct 21, 2023 / Business Wire / Personalis, Inc . (Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking... Read More

FREMONT, Calif. / Oct 19, 2023 / Business Wire / Personalis, Inc . (Nasdaq: PSNL), a leader in precision oncology, today announced that a late-breaking abstract featuring data for the company’s NeXT Personal ® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection, has been accepted and selected for a proffered paper presentation at the 2023 European Society for Medical Oncology (ESMO) Congress, on... Read More

Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality FREMONT, Calif. / Oct 18, 2023 / Business Wire / Personalis, Inc . (Nasdaq: PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha... Read More

FREMONT, Calif. / Aug 29, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the 21 st Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023 at 4:55 p.m. Eastern Time in New York, NY at the Sheraton New York. About Personalis, Inc. At Personalis, we are transforming the active... Read More

FREMONT, Calif. / Aug 24, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the Compensation Committee of its Board of Directors granted, between the dates of May 15, 2023 and August 15, 2023, non-qualified stock options to purchase an aggregate of 43,000 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 24,500 shares of... Read More

FREMONT, Calif. / Aug 08, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2023 and provided recent business highlights. Recent Business Updates Announced a collaboration with National Cancer Center Hospital East and Ono Pharmaceutical Co. Ltd to perform exploratory biomarker analysis using... Read More

FREMONT, Calif. / Aug 01, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences: 8 th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Participating on Monday, August 14, 2023 Sidoti Virtual Micro Cap Conference Presenting on Wednesday, August 16, 2023 at 12:15... Read More

FREMONT, Calif. / Jul 25, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2023 financial results on Tuesday, August 8, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and... Read More

Infringed patents part of industry-leading intellectual property position in whole genome, tumor-informed minimal residual disease testing FREMONT, Calif. / Jun 26, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL) today announced that the company has filed a second patent infringement suit against Foresight Diagnostics Inc. Personalis is seeking injunctive relief and monetary damages. This suit brings the total number... Read More

FREMONT, Calif. / Jun 13, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc.,... Read More

New findings emphasize the potential of company’s ultra-sensitive MRD platform for longitudinal disease monitoring and the study of dynamic tumor evolution FREMONT, Calif. / May 30, 2023 / Business Wire / Personalis, Inc . (Nasdaq: PSNL) today announced it will present new clinical data as scientific posters at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, which convenes from June 2-6, 2023, in... Read More

Multicenter VOLTAGE-2 Phase II Trial Will Conduct Exploratory Biomarker Analysis Using Highly-Sensitive Genomic Platforms from Personalis FREMONT, Calif. & KASHIWA, Japan & OSAKA, Japan / May 16, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), National Cancer Center, and Ono Pharmaceutical Co., Ltd. today announced they have entered into a collaborative agreement to examine the efficacy and safety of nivolumab , an... Read More

FREMONT, Calif. / May 03, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2023 and provided recent business highlights. Recent Business Updates Announced a collaboration with Cancer Research UK, University College London, and the Francis Crick Institute to utilize our ultra-sensitive NeXT... Read More

FREMONT, Calif. / May 02, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL) today announced it has partnered with the Academic Breast Cancer Consortium (ABRCC) and Criterium to carry out a prospective clinical trial, B-STRONGER-1 (Breast Cancer-Minimal Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I), to evaluate the clinical performance of the NeXT Personal ® test for... Read More

FREMONT, Calif. / Apr 19, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent... Read More

FREMONT, Calif. / Apr 05, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19 at 3:00 p.m. Eastern Time. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough... Read More

Personalis’ NeXT Personal® liquid biopsy assay will be deployed in a collaboration for TRACERx to assess approaches for earlier lung cancer recurrence post-surgery and for relapse FREMONT, Calif. & LONDON / Apr 05, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), Cancer Research UK’s Cancer Research Horizons, University College London (UCL), and the Francis Crick Institute today announced a collaboration to deploy... Read More

New findings reinforce potential of company’s highly-sensitive MRD offerings for earlier recurrence detection and therapy response monitoring FREMONT, Calif. / Mar 22, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes from April 14-19, 2023 in Orlando,... Read More

FREMONT, Calif. / Mar 07, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it will continue its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global science-led biopharmaceutical company, to explore ultra-sensitive molecular residual disease (MRD) measurement, including clinically relevant and personalized variant tracking, for clinical... Read More

FREMONT, Calif. / Mar 02, 2023 / Business Wire / Personalis, Inc. ( Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Board of Directors has appointed Christopher Hall as Chief Executive Officer (CEO) and a member of the Board, effective immediately, in addition to his role as President. Hall will lead the Company’s efforts to drive a new paradigm for the active management of... Read More

FREMONT, Calif. / Feb 23, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent business highlights. Recent Business Highlights Announced a continuing partnership with Moderna to provide genomic testing for their upcoming clinical studies evaluating... Read More

FREMONT, Calif. / Feb 09, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its... Read More

FREMONT, Calif. / Feb 03, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940, an... Read More

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2022. Personalis estimates revenue of approximately $16.7 million for the fourth quarter of 2022 and approximately $65.0 million for the full year of 2022, which exceeds the company’s previous full year guidance range of $63.0 to $64.0... Read More